Literature DB >> 16038110

Hypercatabolism of IgG in mice with lupus-like syndrome.

J Zhou1, L M Pop, V Ghetie.   

Abstract

The metabolism of radioiodinated mouse IgG was studied in mice with lupus-like syndrome before and after the onset of the disease. Before the onset of the disease, the pharmacokinetic parameters of IgG in MLR-1pr and Pristane-primed Balb/c mice were within the normal range of values. After the onset of the disease a considerable increase in the catabolic rate of IgG was recorded abbreviating its half life to less than one third of the normal value. The increased catabolism of IgG could not be related to the concentration--catabolism effect or to the presence of rheumatoid factor and autoantibody or to the IgG loss through the kidney and gastrointestinal tract. The hypercatabolism of IgG was explained by disease-induced impairment of the function of the receptor FcRn, which regulates the homeostasis of IgG.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16038110     DOI: 10.1191/0961203305lu2129oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

Review 1.  Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn.

Authors:  Kristi Baker; Shuo-Wang Qiao; Timothy Kuo; Kanna Kobayashi; Masaru Yoshida; Wayne I Lencer; Richard S Blumberg
Journal:  Semin Immunopathol       Date:  2009-06-03       Impact factor: 9.623

Review 2.  Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.

Authors:  Yulia Vugmeyster; John Harrold; Xin Xu
Journal:  AAPS J       Date:  2012-07-14       Impact factor: 4.009

3.  Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-04-30       Impact factor: 4.009

4.  In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus.

Authors:  Yulia Vugmeyster; Heath Guay; Pamela Szklut; Ming D Qian; Macy Jin; Angela Widom; Vikki Spaulding; Frann Bennett; Leslie Lowe; Tatyana Andreyeva; David Lowe; Steven Lane; George Thom; Viia Valge-Archer; Davinder Gill; Deborah Young; Laird Bloom
Journal:  MAbs       Date:  2010-05-23       Impact factor: 5.857

Review 5.  Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.

Authors:  Katherine L Gill; Krishna K Machavaram; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

6.  Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.

Authors:  Atsuhiko Maeda; Yuki Iwayanagi; Kenta Haraya; Tatsuhiko Tachibana; Genki Nakamura; Takeru Nambu; Keiko Esaki; Kunihiro Hattori; Tomoyuki Igawa
Journal:  MAbs       Date:  2017-04-07       Impact factor: 5.857

Review 7.  Current perspectives on fetal and neonatal alloimmune thrombocytopenia - increasing clinical concerns and new treatment opportunities.

Authors:  Heidi Tiller; Anne Husebekk; Maria Therese Ahlen; Tor B Stuge; Bjørn Skogen
Journal:  Int J Womens Health       Date:  2017-04-19

Review 8.  Understanding Inter-Individual Variability in Monoclonal Antibody Disposition.

Authors:  Veena A Thomas; Joseph P Balthasar
Journal:  Antibodies (Basel)       Date:  2019-12-04

9.  Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome.

Authors:  Willem Jan R Fokkink; Sander J van Tilburg; Brenda C M de Winter; Sebastiaan D T Sassen; Pieter A van Doorn; Birgit C P Koch; Bart C Jacobs
Journal:  Clin Pharmacokinet       Date:  2022-07-04       Impact factor: 5.577

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.